GeoVax Announces Issuance of Ebola Vaccine Patent
24 Luglio 2023 - 3:00PM
via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a
biotechnology company developing immunotherapies and vaccines
against cancers and infectious diseases, today announced
that the U.S. Patent and Trademark Office has issued Patent No.
11,701,418 B2 to GeoVax, pursuant to the Company’s patent
application No. 15/543,139 titled “Replication-Deficient Modified
Vaccinia Ankara (MVA) and Matrix Protein (VP40).”
The claims granted by the patent generally cover GeoVax’s vector
platform for expressing ebolavirus antigens in virus-like particles
(VLPs) utilizing an MVA viral vector. The claims encompass multiple
ebolavirus strains, including Sudan ebolavirus, Zaire ebolavirus,
Taï Forest ebolavirus, and Reston ebolavirus.
GeoVax previously demonstrated that a single intramuscular (IM)
dose of its vaccine candidate, GEO-EM01, provided 100% protection
in rhesus macaques challenged with a lethal dose of Zaire
ebolavirus (EBOV). GEO-EM01 is based on the Company’s novel MVA-VLP
platform, which generates noninfectious VLPs in the individual
being vaccinated. VLPs mimic a natural infection, triggering the
body to produce a robust and durable immune response with both
antibodies and T cells.
Additionally, in July 2021, the Company announced results of
preclinical efficacy studies of its Sudan ebolavirus (SUDV) vaccine
candidate, in which a single dose of the vaccine protected 100% of
small animals challenged with a lethal dose of SUDV. Dr. Jason
Comer of Sealy Institute for Vaccine Sciences, University of Texas
Medical Branch (UTMB), recently discussed GeoVax’s Sudan virus
vaccine efficacy. His presentation to the Global Health
Preparedness Strategy and Priority Pathogens session at the 23rd
Annual World Vaccine Congress demonstrated partial protection
following lethal Sudan virus challenge in a rigorous cynomolgus
macaque model. This research project has been funded in whole or in
part with Federal funds under a Preclinical Services Contract from
the National Institute of Allergy and Infectious Diseases, part of
the National Institutes of Health.
David Dodd, GeoVax President and CEO, commented, “While our
focus and development priorities continue to be our COVID-19
vaccine and cancer immunotherapy programs, developing vaccines
against lethal hemorrhagic fever viruses represents our commitment
to addressing highly fatal endemic threats throughout the world, as
well as our support of critically important biodefense initiatives.
This patent allowance adds to our growing portfolio of wholly
owned, co-owned, and in-licensed intellectual property, now
standing at over 115 granted or pending patent applications spread
over 24 patent families.”
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding
GeoVax’s business plans. The words “believe,” “look forward to,”
“may,” “estimate,” “continue,” “anticipate,” “intend,” “should,”
“plan,” “could,” “target,” “potential,” “is likely,” “will,”
“expect” and similar expressions, as they relate to us, are
intended to identify forward-looking statements. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our financial condition, results
of operations, business strategy and financial needs. Actual
results may differ materially from those included in these
statements due to a variety of factors, including whether: GeoVax
is able to obtain acceptable results from ongoing or future
clinical trials of its investigational products, GeoVax’s
immuno-oncology products and preventative vaccines can provoke the
desired responses, and those products or vaccines can be used
effectively, GeoVax’s viral vector technology adequately amplifies
immune responses to cancer antigens, GeoVax can develop and
manufacture its immuno-oncology products and preventative vaccines
with the desired characteristics in a timely manner, GeoVax’s
immuno-oncology products and preventative vaccines will be safe for
human use, GeoVax’s vaccines will effectively prevent targeted
infections in humans, GeoVax’s immuno-oncology products and
preventative vaccines will receive regulatory approvals necessary
to be licensed and marketed, GeoVax raises required capital to
complete development, there is development of competitive products
that may be more effective or easier to use than GeoVax’s products,
GeoVax will be able to enter into favorable manufacturing and
distribution agreements, and other factors, over which GeoVax has
no control.
Further information on our risk factors is contained in our
periodic reports on Form 10-Q and Form 10-K that we have filed and
will file with the SEC. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor Relations Contact:Rich CockrellCG
Capital404-736-3838govx@cg.capital
Media Contact:Susan
Robertssr@roberts-communications.com202-779-0929
Grafico Azioni GeoVax Labs (NASDAQ:GOVXW)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni GeoVax Labs (NASDAQ:GOVXW)
Storico
Da Set 2023 a Set 2024